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Abstract
Background: Federal guidelines now recommend supplemental HIV RNA testing for persons at high risk for acute HIV
infection. However, many rapid HIV testing sites do not include HIV RNA or p24 antigen testing due to concerns about cost,
the need for results follow-up, and the impact of expanded venipuncture on clinic flow. We developed criteria to identify
patients in a municipal STD clinic in San Francisco who are asymptomatic but may still be likely to have acute infection.
Methods: Data were from patients tested with serial HIV antibody and HIV RNA tests to identify acute HIV infection. BED-
CEIA results were used to classify non-acute cases as recent or longstanding. Demographics and self-reported risk behaviors
were collected at time of testing. Multivariate models were developed and preliminarily evaluated using predictors
associated with recent infection in bivariate analyses as a proxy for acute HIV infection. Multivariate models demonstrating
$70% sensitivity for recent infection while testing #60% of patients in this development dataset were then validated by
determining their performance in identifying acute infections.
Results: From 2004–2007, 137 of 12,622 testers had recent and 36 had acute infections. A model limiting acute HIV
screening to MSM plus any one of a series of other predictors resulted in a sensitivity of 83.3% and only 47.6% of patients
requiring testing. A single-factor model testing only patients reporting any receptive anal intercourse resulted in 88.9%
sensitivity with only 55.2% of patients requiring testing.
Conclusions: In similar high risk HIV testing sites, acute screening using ‘‘supplemental’’ HIV p24 antigen or RNA tests can
be rationally targeted to testers who report particular HIV risk behaviors. By improving the efficiency of acute HIV testing,
such criteria could facilitate expanded acute case identification.
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Introduction
In the U.S., HIV antibody testing (using either a rapid test or a
laboratory-based enzyme immunoassay (EIA) for antibody screen-
ing) remains the most widely used approach to diagnosing HIV
infection [1]. However, even the most sensitive antibody tests on
the U.S. market today are unable to detect most infections until
approximately one month after the onset of infection, as antibodies
have not yet been generated in sufficient abundance to trigger a
positive reaction to the test. Prior to 2009, guidelines for HIV
testing in the U.S. [2] therefore recommended supplemental HIV
RNA testing for persons with a suspected acute retroviral
syndrome (based on report of both recent high-risk behavior and
compatible clinical symptoms).
Recent data from U.S. testing programs have shown that many
HIV infected people who seek HIV testing do so during the initial,
antibody-negative acute phase of their infection, due to concern
over a specific risk incident, repeated high risk behavior, or
occasionally due to symptoms [3–6]. This can lead to negative
HIV antibody results in many cases of true HIV infection. Missing
the diagnosis of acute HIV infection in such antibody-negative,
HIV infected individuals is particularly concerning due to the very
high potential for sexual HIV transmission that is associated with
the initial acute phase of infection [7–9]. To address the HIV
prevention challenge inherent in identifying HIV testers with acute
HIV infection, the U.S. Centers for Disease Control and
Prevention (CDC) and Association of Public Health Laboratories
(APHL) have issued preliminary algorithms [10] recommending
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or report recent high-risk exposure undergo supplemental testing
using an assay capable of detecting either HIV RNA or HIV p24
antigen to rule out acute HIV infection (See Figure 1).
Accordingly, simply scheduling a future appointment to retest
high-risk persons at a later time using less expensive EIA tests is
insufficient in high-prevalence areas; targeting RNA or p24
antigen testing as described in this paper allows newly-infected
individuals in the initial acute phase to cease behaviors which
could unwittingly transmit the virus to sexual partners, as well as to
seek medical care very close to the time of infection.
There is a trade-off between the cost and effort needed to
identify acute HIV infections and the number of acute infections
identified. Specifically, the HIV RNA or HIV p24 antigen tests
necessary to identify acute HIV infection can introduce additional
cost and complexity to HIV testing algorithms. For some HIV
testing sites, especially those using point-of-care rapid HIV testing,
simply collecting a tube of blood to allow HIV RNA or p24
antigen testing from every person could create major cost and
clinic flow problems. For these reasons, HIV RNA or p24 antigen
testing is not part of testing at most sites for voluntary HIV
counseling and testing, and individuals with hyper-infectious acute
HIV infection who do seek testing are commonly given ‘‘negative’’
HIV test results [4–6].
In an attempt to reconcile logistic and cost concerns with
prevention priorities, some public health programs have expressed
interest in the ‘targeted’ use of acute HIV testing. One study in
North Carolina [11] found that testing for acute HIV infection
could have been effectively targeted by limiting the use of HIV
RNA or p24 antigen testing to ‘‘high risk’’ clinics (e.g. dedicated
HIV counseling and testing sites, STD clinics, jails and public
health field investigations), and to geographic areas with
substantial prevalence of HIV infection (counties reporting .1
new HIV case per 2 years). Sherlock and colleagues completed a
survey of current RNA pooling practice in the U.S. in 2007 [12],
reviewing practices at all publicly-funded acute HIV detection
programs. At that time, only 7 State, County, or City HIV testing
programs offered pooled HIV RNA testing and only one (Seattle-
Figure 1. Performance of various HIV assays with respect to rise and fall of CD4 count, HIV antibodies, HIV viral load, and viral
shedding over time after infection. Black bars to the left of assay names indicate ability of that assay to detect HIV infection.
doi:10.1371/journal.pone.0021813.g001
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eligible population to men who have sex with men (MSM). To
date, neither the preliminary CDC/APHL guidelines nor the
scientific literature provide additional guidance as to which HIV
testers in developed world settings with substantial rates of HIV
may actually be at risk of acute HIV infection.
To address this critical gap in knowledge, the present study was
performed to develop and evaluate formal criteria for targeting
individuals at high risk of acute HIV infection among patients
presenting for HIV testing at the San Francisco City Clinic, a
municipal STD clinic and site for HIV voluntary counseling and
testing in San Francisco, California. This analysis was attempted
to systematically determine criteria that would greatly reduce
missed acute infections while simultaneously minimizing the
proportion of overall clinic patients tested, reducing cost and
burden on clinic flow and improving the efficiency of a
hypothetical supplemental (HIV RNA/p24 antigen) program.
These criteria could then be used by HIV testing clinics wishing to
offer a targeted supplemental testing program to improve the
effectiveness of HIV testing services.
Methods
Study participants included all patients who came into the San
Francisco City Clinic (SFCC) for HIV testing between January
2004 and December 2007. SFCC is a municipal sexually
transmitted disease clinic run by the San Francisco Department
of Public Health that offers free, confidential HIV testing for youth
and adults in San Francisco. Beginning in October 2003, SFCC
has offered screening for acute HIV infection by testing HIV
antibody-negative specimens for HIV RNA, using a specimen
pooling approach to reduce cost and maximize efficiency. (Using
this method, aliquots of 10 HIV antibody-negative specimens are
pooled and then tested for HIV-1 RNA [Versant HIV-1 RNA 3.0
Assay, Bayer Corp., Berkeley, CA, USA or Abbott m2000
RealTime HIV-1 Assay, Abbott Molecular, Des Plaines, IL,
USA]; if a pooled sample is HIV RNA-positive, each specimen
from the pool is then tested individually to determine the HIV-
infected individual. This pooling method was chosen after previous
validation in San Francisco [5]. Pool size represents a compromise
between the maximum cost-efficiency of large pools and the
optimal sensitivity and turnaround time with smaller pools [13].
The theoretical limit of detection for any of the RNA tests used
can be extrapolated by multiplying the test sensitivity as stated in
the package insert by the factor of dilution. For example, the
Versant HIV-1 RNA 3.0 Assay has a stated limit of detection of 75
copies [14]; with a .10 dilution the theoretical limit of detection is
750 copies. Similarly, the theoretical limit of detection for the
Abbott m2000 RealTime HIV-1 Assay was 400 copies with this
pooling strategy [15].) During the study period, HIV antibody
testing was performed using one of several FDA-approved
antibody tests, including rapid point-of-care HIV tests [OraQuick
ADVANCE, OraSure Technologies, Inc., Bethlehem, PA, USA]
and HIV antibody-only immunoassays [Vironostika HIV-1
Microelisa, BioMe ´rieux Inc., Durham, NC, USA or Genetic
Systems HIV-1/2 plus O EIA, BioRad Laboratories, Redmond,
WA, USA]. Individuals with antibody negative but HIV RNA
positive results were re-tested on subsequent samples using an
IgM-sensitive (3
rd-generation) antibody immunoassay [Genetic
Systems HIV-1/2 plus O EIA, BioRad Laboratories, Redmond,
WA, USA] and Western blot [Genetic Systems HIV-1 Western
Blot, BioRad Laboratories, Redmond, WA, USA] or Immuno-
fluorescence Assay (IFA) [Fluorognost HIV-1 IFA, Sanochemia
Pharmazeutika AG, Vienna, Austria]. In addition to this clinical
HIV testing, in most cases individuals with HIV antibody-positive
test results had blood plasma submitted for incidence testing using
the BED Capture Enzyme Immunoassay (BED-CEIA) [Sedia
Biosciences Corp., Portland, OR, USA], which is used to classify
antibody-positive individuals with regard to having recent (,6
months’ duration) or longstanding HIV infection for surveillance
purposes.
In this analysis, individuals were classified as having acute HIV
infection, likely recent HIV infection or longstanding (non-acute,
non-recent) infection based on results of the complete clinical and
surveillance testing algorithm. Cases were classified as acute HIV
infection if individual testing for HIV RNA was repeatedly
reactive but results of the Western blot or IFA were negative or
indeterminate [16]. Cases with confirmed positive antibody testing
but with a BED-CEIA normalized optical density (ODn),0.8
were classified as recent HIV infection. Cases with a BED-CEIA
ODn.0.8 were classified for the purposes of analysis as having
longstanding HIV infection. Self-reported demographic and
behavioral risk factors were systematically collected during the
initial clinic visit. All procedures were conducted as part of
standard clinical and public health practice and all data analysis
was done on de-identified data. As these were de-identified public
health records undergoing retrospective analyses for public health
improvement purposes, no informed consent specific to this study
was sought from participants, and this study was considered
exempt from human subjects considerations in accordance with
the Code of Federal Regulations, Title 45.
This cross sectional analysis utilized an adaptation of the
approach used by Miller et al. [17] in North Carolina and Powers
et al. [18] in Malawi. For an initial model development phase, a
series of candidate models were developed for the testing
population using the outcome of having recent HIV infection.
Actual performance of these candidate models in identifying
individuals with acute HIV infection was validated using the
smaller number of acute HIV infection outcomes in a second
analytic step. Model development and validation procedures used
a common set of ‘‘controls’’ (that is, patients testing both HIV
antibody and RNA negative). Patients with longstanding (non-
acute, non-recent) HIV infection were excluded from model
development analyses.
It is expected that many individuals testing at a location such as
a municipal STD clinic will repeatedly test, sometimes multiple
times within one year; as such it is imperative that we assess
performance of multiple criteria within a population of repeat
testers. As we were attempting to validate the practical application
of targeting criteria based on risk behaviors specific to the pre-test
interval, each testing interaction for a repeating individual within
our dataset was treated as a unique testing encounter.
In bivariate analyses, potential associations between HIV
infection status and demographic and risk behavior were tested
using Pearson’s chi square or Fisher’s Exact test where expected
cell values were less than 5. Those characteristics that reached
p,0.2 in bivariate analyses were then used as candidate predictors
in multivariate models during model development using a manual
backward selection procedure. Because there were several ways to
consider the risk of anal intercourse including a) any vs. specifically
receptive intercourse, and b) with vs. without consistent condom use,
separate but similar groups of models were created with different
definitions of this risk factor as one of the input variables.
With the goal of creating a simple set of criteria for RNA testing
to streamline clinical decision-making, the same collections of
variables were then used to create simple checklists. In this
checklist approach, having a specified minimum number of
characteristics from a list would determine the need for RNA
A Model for Targeted Acute HIV Screening
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e21813testing. Performance of the checklists was assessed in terms of
sensitivity, specificity, and proportion of patients in which RNA
testing was indicated. Because the San Francisco HIV epidemic
has predominantly affected MSM, a modified checklist approach
was further considered, in which RNA testing would be indicated
only for MSM with one or more additional characteristics from a
checklist. Finally, RNA testing was considered for anyone who
mentioned engaging in any anal intercourse, or specifically
receptive anal intercourse alone (in separate models).
Models with $70% sensitivity to detect recent infection
(indicating potentially adequate sensitivity) and that resulted in
RNA testing of #60% of patients (indicating a reduction in the
proportion tested greater than the reduction in sensitivity) were
chosen for further validation. These selected models were then
validated using acute infection cases, and performance character-
istics including area under the receiver operator characteristic
(ROC) curve were calculated for all selected models.
Results
From 2004 though 2007, there were 12,622 tests for HIV at the
San Francisco City STD Clinic. Of these, 233 (1.9%) people had
longstanding HIV infection and were not included in model
development. The study population included 137 (1.1%) people
with recent HIV infection, 36 (0.29%) with acute infection, and
12,216 uninfected people who comprised the comparison group
for all analyses. Because of missing demographic data, 3 people
were omitted from model development, all of whom had tested
HIV negative.
The median age of testers was 32 years (IQR: 26–39 years).
Fifty four percent of patients were white, 20% were Latino, 10%
Black, and the remaining 16% Asian, Native American, or
multiethnic (the latter were grouped together because of low rates
of recent infection compared with other demographic groups).
The study population was 85% male, and 75% MSM. Four
percent reported a history of injection drug use. Characteristics
that were significantly associated with recent infection in bivariate
analyses included race/ethnicity, gender, sexual orientation (self
identified as gay/lesbian/bisexual/queer/questioning (GLBQQ)
or ‘‘other’’, or defined by behavior as MSM), history of anal
intercourse (using any definition including receptive or insertive or
both, and with or without consistent condom use, and regardless of
gender), sex with a known HIV positive partner, history of
injection drug use, and recent history of a sexually transmitted
infection (Table 1). Race/ethnicity was not included in multivar-
iate models because of potential misunderstanding and misrepre-
sentation of the race/ethnicity variable, as well as ethical concerns
about the use of race or ethnicity to determine eligibility for a
particular set of healthcare services [19–20]. Gender was also left
out of multivariate models because of covariance with MSM. Age
was included in model development as a final a priori predictor, but
was eventually dropped from the models because it proved to be
not statistically significant, unlike the other candidate predictors.
(Note: results of models were similar whether self-identified sexual
orientation (GLBQQ/Other) or behaviorally-defined MSM was
used as a starting point. Models with MSM are presented here.)
Sets of logistic models with different definitions of anal
intercourse followed similar patterns in the backwards selection
procedure, dropping age and STD history for a reduced model
with anal intercourse, history of a known HIV positive partner,
history of injection drug use, and any reported male-male sexual
behavior as predictors. Unprotected receptive anal intercourse was
more strongly associated with recent infection than any other
definition of anal intercourse, and full and reduced models using
unprotected receptive anal intercourse are presented in Table 2.
The strongest positive associations with recent infection were with
unprotected receptive anal intercourse (OR=2.82, 95% CI: 1.97–
4.04), and any reported male-male sexual behavior (OR=2.76,
95% CI: 1.42–5.40). Risk of recent infection was also higher for
individuals reporting history of a known HIV positive partner
(OR=2.14, 95% CI: 1.49–3.06), and history of injection drug use
(OR: 2.19, 95% CI: 1.21–3.98).
In addition to creating checklists as a simple tool for clinical
decision making about whether to send specimens for RNA testing,
creation ofa riskscorealgorithm based onlogisticmodelcoefficients
was considered, in the manner of Powers and colleagues [17].
However, in this study population, where multivariate adjusted risks
and therefore logistic model coefficients were all within a narrow
range, this approach effectively reduced to a simple, unweighted
checklist approach because predictors were all given equal weight.
Several checklist models met the pre-determined definition of
acceptable performance (#60% patients tested; $70% sensitivity
for recent infection) and were further validated with respect to the
outcome of acute infection (Table 3). One of the best performing
checklists was based on Table 2, model 1, and involved RNA
testing for anyone with two or more of the following character-
istics: male-male sexual behavior, unprotected receptive anal
intercourse, history of a known HIV positive partner, history of
injection drug use, or recent history of a sexually transmitted
infection. This checklist resulted in RNA testing for 49.7% of
patients undergoing RNA testing and a sensitivity of 83.3% (95%
CI: 67.2–93.6%) to detect acute cases (Table 3, model 1). A
checklist that indicated testing only for people reporting male-male
sexual behavior who had one or more other key characteristics
(unprotected receptive anal intercourse, history of a known HIV
positive partner, history of injection drug use, or recent history of a
sexually transmitted infection) had similar performance (Table 3,
model 3). This latter model resulted in testing 47.6% of patients for
HIV RNA and the model had 83.3% (95% CI: 67.2–93.6%)
sensitivity to detect acute infection.
Finally, simplified models were evaluated, in which different risk
factors were considered as single criteria for supplemental testing;
results are shown in Table 3. Two of these simple models—
focusing on any unprotected anal intercourse or any receptive anal
intercourse as a single criterion for testing—performed nearly as
well as the more complicated checklists. Using unprotected anal
intercourse alone (Table 3, model 5) resulted in 43.0% of patients
tested and sensitivity of 75.0% (95% CI: 57.8–87.9%) for acute
infection. Using any receptive anal intercourse alone (Table 3,
model 6) resulted in 55.2% of patients being tested and a sensitivity
of 88.9% (95% CI: 73.9–96.9%) for acute infection.
Results of the ROC area under the curve (AUC) analysis for the
final models (Table 3) highlighted that the performance of our
final models were largely similar. However, two of the models with
the greatest ROC AUC had substantially lower sensitivity for
acute infection (69.4 and 75.0%) than other candidate models.
Ultimately, this parameter was not found to be useful in deciding
which model had the best overall performance.
Discussion
This San Francisco, STD clinic-based study found that that
simple criteria based on behavioral risk factors for acute HIV
infection performed well as clinical prediction rules to identify
individuals with a particularly high risk of acute HIV infection.
Results suggest that if such criteria were used to target the use of
HIV RNA or p24 antigen testing at similar sites, one could reduce
the need for this type of testing by about half, while still identifying
A Model for Targeted Acute HIV Screening
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show that even in high prevalence/high risk areas, additional
criteria related to self-report of HIV risk behavior could be used
for highly effective targeting of HIV RNA or p24 antigen-based
acute HIV testing—allowing more efficient use of these acute HIV
screening tests with only a modest decrease in acute case finding.
The factors most strongly associated with having acute HIV
infection in the STD clinic population were male biological sex,
gay identity, male-male sexual behavior, and anal intercourse.
Remarkably, even very simple criteria (for example, a single
behavioral risk factor such as receptive anal intercourse) perfor-
med nearly as well as more complex, multi-variable models. This
may be explained by the degree to which significant sexual risk
factors for having acute HIV infection co-varied in this clinic
population. While it is important to note that no single risk factor
necessarily performed as well as the best checklists evaluated in this
study, the gains in sensitivity, specificity or testing efficiency
associated with the more complex models were modest. The
relatively good performance of simple models indicates that in
clinic settings where detailed risk factors are not routinely
collected, single risk factors could potentially be used effectively
to target acute HIV testing.
Missing even a few cases of acute HIV infection is undesirable,
and the use of comprehensive testing algorithms for all patients at
Table 1. Characteristics, prevalence of longstanding and recent HIV infection, and associations with recent HIV infection among
persons undergoing HIV testing at the San Francisco City Clinic from 2004–2007 (development data; n=12622).
Longstanding
infection Recent infection
Characteristic Levels
Population
Frequency % (n/N)
Prevalence %
(n/N)
1
Prevalence %
(n/N)
2
OR
(95% CI) p-value
Total population 100% (12622) 1.9% (233/12449) 1.1% (137/12353)
Age
3 ,=40 years 78.1% (9852/12619) 2.1% (57/2736) 1.2% (112/9646) 1.26 (0.81–1.95) 0.30
.40 years 21.9% (2767/12619) 1.8% (176/9710) 0.9% (25/2704) Reference
Race/ethnicity Black 10.3% (1303/12606) 2.6% (33/1278) 1.5% (19/1264) 1.45 (0.87–2.43) 0.014
Latino 19.9% (2503/12606) 2.7% (65/2457) 1.5% (37/2429) 1.47 (0.99–2.20)
Mixed/Other 16.1% (2034/12606) 1.6% (32/2019) 0.6% (12/1999) 0.58 (0.31–1.06)
White 53.7% (6766/12606) 1.5% (103/6679) 1.0% (69/6645) Reference
Gender Male 85.2% (10749/12616) 2.1% (223/10578) 1.3% (135/10490) 11.06 (2.73–44.70) ,0.0001
Trans/Other 1.3% (165/12616) 3.6% (6/165) 0% (0/159) 0 (undefined)
Female 13.5% (1702/12616) 0.2% (4/1700) 0.1% (2/1698) Reference
Sexual Orientation GLBQQ/Other
4 75.2% (9439/12554) 2.4% (219/9277) 1.4% (126/9184) 4.30 (2.26–8.20) ,0.0001
Straight 24.8% (3115/12554) 0.4% (13/3105) 0.3% (10/3102) Reference
MSM MSM 75.0% (9472/12622) 2.3% (217/9309) 1.4% (127/9219) 4.36 (2.29–8.32) ,0.0001
Not MSM 25.0% (3150/12622) 0.5% (16/3140) 0.3% (10/3134) Reference
Anal intercourse (AI)
5 Any AI 71.6% (9038/12622) 2.2% (198/8883) 1.4% (121/8806) 3.07 (1.82–5.19) ,0.0001
No AI 28.4% (3584/12622) 1.0% (35/3566) 0.5% (16/3547) Reference
Unprotected anal intercourse (uAI)
5 Any uAI 43.7% (5515/12622) 2.8% (148/5389) 1.9% (99/5340) 3.47 (2.38–5.05) ,0.0001
No uAI 56.3% (7107/12622) 1.2% (85/7060) 0.5% (38/7013) Reference
Receptive anal intercourse (RAI)
5 Any RAI 55.8% (7045/12622) 2.5% (173/6907) 1.6% (106/6840) 2.78 (1.86–4.16) ,0.0001
None 44.2% (5577/12622) 1.1% (60/5542) 0.6% (31/5513) Reference
Unprotected receptive anal
intercourse (uRAI)
5
Any uRAI 31.2% (3938/12622) 3.2% (123/3828) 2.2% (85/3790) 3.76 (2.65–5.31) ,0.0001
None 68.8% (8684/12622) 1.3% (110/8621) 0.6% (52/8563) Reference
Injection drug use
5 Any IDU 4.2% (531/12622) 2.3% (12/518) 2.5% (13/519) 2.43 (1.36–4.33) 0.002
None 95.8% (12091/12622) 1.9% (221/11931) 1.1% (124/11834) Reference
Any sex with known HIV+ partner
5 Yes 17.2% (2168/12622) 3.2% (68/2102) 2.5% (51/2085) 2.97 (2.09–4.21) ,0.0001
No 82.8% (10454/12622) 1.6% (165/10347) 0.8% (86/10268) Reference
Recent STD
6 Yes 32.9% (4153/12606) 2.4% (96/4077) 1.4% (58/4039) 1.52 (1.08–2.14) 0.016
No 67.1% (8453/12606) 1.5% (121/8356) 1.0% (79/8314) Reference
1Longstanding HIV prevalence: prevalence of longstanding infection over the entire study period (2004–2007) (note: recent and acute infections were excluded from
the denominator).
2Recent HIV prevalence: prevalence of recent infection over the entire study period (2004–2007) (note: acute and longstanding infections were excluded from the
denominator).
3Age, median (IQR): 32 yrs (26–39).
4GLBQQ/Other group includes gay, lesbian, bisexual, queer, ‘‘don’t know’’ (questioning), and ‘‘other’’.
5All risk behaviors occurring since time of last HIV test or within the past 2 years, whichever is shorter.
6Sexually transmitted infection diagnosed since time of last HIV test or within the past 2 years, whichever is shorter.
doi:10.1371/journal.pone.0021813.t001
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criteria for targeting RNA or p24 antigen testing could apply
mainly to sites where performing the additional procedures
involved for such testing (e.g., phlebotomy) is problematic due to
cost, personnel, space, or other factors.
These results are subject to several limitations. When dealing
with sensitive, self-reported data, reporting bias may be a factor.
Furthermore, a number of data fields had high rates of missing
data or inconsistent information, which precluded their use in the
analysis. Another potential limitation is the use of BED-CEIA test
results for classification of cases as having ‘‘recent’’ or ‘‘long-
standing’’ infection, as this test is subject to overestimation of
recent infections [21–23]. However, the performance of recent
infection status (based on BED results) as a population-level proxy
measure for acute HIV, when validated against the acute infection
outcome, was consistent with the previous findings of Miller, et al,
who used the Vironostika LS-EIA in North Carolina [24]. In
addition, the criteria developed were in a city with an HIV
epidemic that is heavily concentrated among gay men [25] and
cannot be considered generalizable to other cities with distinct
HIV epidemiology. Specifically, so few women were included in
the raw data that we did not have sufficient power in this analysis
to assess the odds associated with vaginal intercourse or other
sexual behaviors related specifically to women. Additionally,
Table 2. Full multivariable predictive model, and models reduced through backwards selection, for recent HIV infection among
persons undergoing HIV testing at the San Francisco City Clinic from 2004–2007 (development data; n=12350; excludes acute and
longstanding infections and n=3 HIV negative people with missing demographic data).
Model 1: Full Model Model 2: Reduced Model
Characteristic co-efficient OR (95% CI) p-value co-efficient OR (95% CI) p-value
Unprotected RAI
Any 1.019 2.77 (1.93–3.97) ,0.0001 1.037 2.82 (1.97–4.04) ,0.0001
None Referent Referent
HIV+ Partner
Any 0.740 2.10 (1.46–3.01) ,0.0001 0.759 2.14 (1.49–3.06) ,0.0001
None Referent Referent
Injection drug use
Any 0.775 2.17 (1.20–3.94) 0.01 0.785 2.19 (1.21–3.98) 0.01
None Referent Referent
MSM
Any 1.013 2.75 (1.41–5.38) 0.003 1.016 2.76 (1.42–5.40) 0.003
None Referent Referent
Recent STD
Any 0.222 1.25 (0.88–1.76) 0.21
None Referent
doi:10.1371/journal.pone.0021813.t002
Table 3. Performance of models selected during the development stage (using recent infection as the outcome), here validated
using acute HIV infection cases as the outcome.
Model Checklist characteristics
1
Proportion referred for
testing (% [n/N]) Sensitivity (95% CI) Specificity (95% CI) ROC AUC
Model 1 $2 from list: MSM, IDU, +partner, uRAI, STI 49.7% (6086/12249) 83.3% (67.2–93.6) 50.4% (49.5–51.3) 0.669
Model 2 $2 from list: MSM, IDU, +partner, uRAI 37.3% (4573/12249) 75.0% (57.8–87.9) 62.8% (61.9–63.6) 0.689
Model 3 MSM +1 from list: IDU, +partner, uRAI, STI 47.6% (5826/12249) 83.3% (67.2–93.6) 52.5% (51.7–53.4) 0.679
Model 4 Single risk factor: AI 71.2% (8719/12252) 94.4% (81.3–99.3) 28.9% (28.1–29.7) 0.617
Model 5 Single risk factor: uAI 43.0% (5268/12252) 75.0% (57.8–87.9) 57.1% (56.2–58.0) 0.661
Model 6 Single risk factor: RAI 55.2% (6766/12252) 88.9% (73.9–96.9) 44.9% (44.0–45.8) 0.669
Model 7 Single risk factor: uRAI 30.4% (3730/12252) 69.4% (51.9–83.7) 69.7% (68.8–70.5) 0.696
Model 8 uRAI or $2 from list: MSM, IDU, +partner, STI 51.1% (6255/12249) 83.3% (67.2–93.6) 49% (48.1–49.9) 0.662
All models are based on acute HIV infection among persons undergoing HIV testing at the San Francisco City Clinic from 2004–2007 (validation
data; n=12252; excludes recent and longstanding infections).
1Key to checklists: MSM (person is a man who had sex with male partner(s)); IDU (any history of injection drug use); +partner (person had a partner known to be HIV
positive); uRAI (engaged in unprotected receptive anal intercourse); STI (had a sexually transmitted infection within the past 2 years or since the last HIV test); AI
(engaged in any anal intercourse, regardless of sex or gender); uAI (engaged in unprotected anal intercourse, regardless of sex or gender); RAI (engaged in receptive
anal intercourse, regardless of sex or gender); uRAI (engaged in unprotected receptive anal intercourse, regardless of sex or gender).
doi:10.1371/journal.pone.0021813.t003
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low and there were no acute cases among transgender individuals
in our dataset, transgenders did not appear in the criteria;
however, since epidemiological risk profiles in San Francisco [26]
and biological risk factors (e.g. URAI) between trans women and
MSM are so similar, it would be reasonable to interpret our
findings regarding MSM to also apply to trans women. Finally, no
information was collected on the presence or absence of possible
viral-syndrome symptoms from testers.
In summary, this analysis found that simple criteria based on
self-report of HIV risk behavior could be used to target the use of
HIV RNA or p24 antigen-based acute HIV testing, resulting in a
substantially reduced volume of supplemental testing in high risk
settings, while preserving the ability of a testing program to detect
acute HIV infections and ensure accurate HIV case identification.
Given the high likelihood of sexual transmission during the
acute phase of HIV infection, detecting acute HIV infections could
hypothetically impact the spread of HIV in populations, as
described by Powers and colleagues (International AIDS Confer-
ence, 2010). However, in this era of reduced resources for HIV
prevention, the expansion of efforts to identify acute HIV
infections at HIV testing sites will require feasible approaches
that can minimize costs and complexity while maximizing acute
case detection. Expansion of acute HIV testing services to new
areas may be possible with the introduction of simpler assays for
acute HIV detection in the U.S., including approved 4
th
generation immunoassays [27] and rapid tests still in development.
Using acute HIV tests with rational criteria for targeting their use
offers an important opportunity to meet these goals and potentially
influence the course of the HIV epidemic in San Francisco.
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